All Press Releases
Pila Pharma AB announces certification of API
Malmö, Sweden, April 25, 2022 Pila Pharma AB (PILA) today announces that the study material (non-GMP API) to be used in three-month preclinical studies has received a certificate of analysis and is thus ready to use. As announced in August 2021, the production of a new XEN-D0501 API for the planned preclinical safety studies was outsourced to Almac Group. This…
Pila Pharma bygger pipeline – ansöker om Orphan Drug Designation i USA
Malmö, 22 april, 2022 Pila Pharma AB meddelar att bolaget har ansökt om Orphan Drug Designation (särläkemedelsstatus) vid U.S. Food and Drug Administration, FDA, för utvecklingskandidaten XEN-D0501. Syftet är att ta fram en behandling av en sjukdom förknippad med smärta på grund av neurogen inflammation. Pila Pharmas utvecklingskandidat XEN-D0501 är under utveckling för behandling av typ 2-diabetes. Förberedelser pågår enligt…
Pila Pharma builds pipeline – applies for Orphan Drug Designation in the USA
Malmö, 22 April, 2022 Pila Pharma AB announces that the company has submitted a request for an Orphan Drug Designation to the U.S. Food and Drug Administration (FDA) for the company’s development candidate XEN-D0501. The aim is to develop a novel treatment of a rare disease associated with pain due to neurogenic inflammation. Pila Pharma's development candidate XEN-D0501 is under development for…